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Abstract This study aims to determine if isoprostanes accu-
rately reflect in vivo lipid peroxidation or whether they are
influenced by the lipid content of the diet. Isoprostanes were
measured in urine of healthy subjects under different conditions
of lipid intake and under conditions of oxidative stress (fasting).
We found that isoprostanes were not influenced by the lipid
content of the diet : the urinary level remained constant over 24 h
as well as over 4 consecutive days when switching from high to
low lipid intake. Urinary isoprostane excretion was increased by
40% following a 24 h fast. We concluded that urinary isoprostane
excretion reflects endogenous lipid peroxidation in vivo.
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1. Introduction
The detection and measurement of lipid peroxidation has
been most frequently used to support the involvement of free
radical reactions in pathophysiological conditions. Lipid per-
oxidation involves a cascade of events. The oxidation process
of polyunsaturated fatty acids (PUFAs) is characterized by
several parameters such as the disappearance of PUFAs, the
appearance of radicals within the PUFAs, the formation of
conjugated dienes and lipid peroxides which are rather unsta-
ble molecules or the formation of aldehydes or alkanes. A
number of methods have been developed to measure these
compounds [1]. However, each method has its limitations
and pitfalls and is often not applicable to all circumstances,
especially when applied to human samples. Indeed, these
methods are often neither speci¢c nor sensitive enough to
monitor small changes in free radical status and lipid perox-
idation in vivo. Therefore, the development of more speci¢c
and sensitive assays to detect and better represent in vivo rates
of lipid peroxidation as an index of free radical generation
and oxidative stress is desirable [2].
In recent years, the measurement of isoprostanes, products
of arachidonic acid formed by free radical-catalyzed reactions,
appears to be a promising assay that might be speci¢c and
sensitive enough to detect in vivo lipid peroxidation [3]. The
isoprostanes are a series of prostaglandin-like compounds,
which are formed from oxidation of arachidonic acid present
in phospholipids by free radical-mediated reactions [4], but
mainly independent of cyclooxygenase enzymes. In 1990,
Roberts and co-workers found that arachidonyl containing
phospholipids in plasma can undergo autooxidation upon
storage, yielding isoprostanes [5]. Later work established
that these compounds could be detected in human plasma,
in urine and in tissues [3]. Morrow et al. reported the detec-
tion of one class of these compounds in vivo, the F2-isopros-
tanes, using gas chromatography/mass spectrometry (GC/MS)
[3]. F2-isoprostanes, in particular 8-iso-prostaglandin F2K (8-
iso-PGF2K) [3], are some of the most abundant forms of iso-
prostanes. Other isoprostanes, such as D2 and E2-isopros-
tanes, are formed by the same non-cyclooxygenase pathway
[6].
Malondialdehyde (MDA), the classical marker of lipid per-
oxidation, was demonstrated to vary in response to absorp-
tion of oxidized lipids present in the diet [7,8]. Therefore,
MDA loses its usefulness as candidate of choice to assess
the in vivo lipid peroxidation in situations where the diet is
changed. In the case of isoprostanes, accumulated evidence
indicates that isoprostanes are produced in in vivo situations
associated with oxidative stress and free radical production
such as in the hepatorenal syndrome [9], in scleroderma [10],
in smokers [11], in interstitial lung disease [12], in ozone ex-
posure [13], in aging [14], in diabetes [15] and in kidney dis-
ease [16]. The level of isoprostanes may be down-regulated
with the administration of antioxidants [17^19]. However,
the impact of a diet on isoprostane excretion is not yet
known. Therefore, the aim of this study is to evaluate, in
healthy subjects, the urinary excretion of isoprostanes in re-
sponse to intake of a low fat diet and after 24 h of fasting. We
demonstrate here that the measurement of urinary isoprostane
levels provides a non-invasive in vivo index of free radical
generation that appears not to be confounded by changes in
the diet.
2. Materials and methods
2.1. Materials
9K, 11K-8 isoprostane and 3,3P,4,4P-tetradeuterated 9K,11K-prosta-
glandin F2 (PGF2-d4) were obtained from Cayman (MI, USA) and
1,3-diethyl-2-thiobarbituric acid was obtained from Sigma (St. Louis,
MO, USA). C18 Bakerbond solid phase extraction (SPE) and a silica
Bakerbond SPE were purchased from Baker (The Netherlands) and
the LK6D silica gel thin layer chromatography (TLC) plates from
Whatman (Clifton, NJ, USA). All commercially available chemicals
and reagents were of analytical grade or greater purity.
2.2. Study design
Four normolipidemic healthy males (age 35 þ 1 years, weight
73 þ 10 kg, BMI 23 þ 3 kg/m2 ; mean þ S.D.) participated in this study.
They ful¢lled the following criteria: normal physical examination, no
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metabolic disorder, fasting plasma triglycerides below 150 mg/dl, fast-
ing plasma cholesterol below 5.19 mM. The volunteers received no
medication from at least 2 weeks before the beginning of the study
until the end of the study. The protocol was approved by the Ethical
Committee of Nestle¤. All volunteers signed informed consent before
entering the study. Body weight, dietary habits and physical activity
remained constant throughout the study period.
Each volunteer participated in two studies.
E¡ect of dietary lipid intake. The ¢rst study was conducted on four
consecutive days, the volunteers ate their usual diet on day 1, a stand-
ardized low fat diet on day 2 and day 3 and then returned to their
regular diet on day 4. The calory supply of the standardized regimen
was designed to be similar to the normal meal (2000 calories/day). The
major modi¢cation was a reduction of the total dietary fat content
from 35 to 5% of total energy, for regular vs. standardized diet,
respectively. The latter was achieved by replacing fat with carbohy-
drate.
E¡ect of fasting. In the second study, the volunteers ate their reg-
ular diet on day 1, went through a 24 h fasting on day 2 and returned
to their regular diet on day 3.
Urine was collected over 24 h in ¢ve di¡erent containers according
to time (fraction 1: 7^10 h, fraction 2: 10^14 h, fraction 3: 14^18 h,
fraction 4: 18^22 h, fraction 5: 22^7 h). The volume of each fraction
was recorded and an aliquot of 25 ml was stored at 380‡C until
analysis. The reconstitution of the 24 h urine sample was performed
by pooling 10% of each of the ¢ve urine samples collected over the
day. This 24 h reconstituted urine was then stored at 380‡C until
analysis.
2.3. Analytical determination
MDA was measured as the MDA-diethylthiobarbituric acid com-
plex [20]. The complex was separated on a 30U3.9 mm I.D. Nova-
Pak C18 column from Millipore (Volketswil, Switzerland) and quan-
ti¢ed with a Waters 490E multiwavelength detector (Millipore, Mil-
ford, MA, USA) at 539 nm.
Isoprostane was determined by a method described by Morrow and
Roberts [21] and Tsikas et al. [22] with some modi¢cations. In a Pyrex
tube, 2 ng of [2H4]PGF2K was added as internal standard and mixed
with 10 ml of water pH 3 and 5 ml of urine. The mixture was adjusted
to pH 3 with 1 N hydrochloric acid. A C18 Bakerbond SPE was pre-
conditioned with 5 ml of methanol and 5 ml of water pH 3. The
sample was loaded on this column, rinsed with 10 ml water pH 3
and 10 ml heptane. The sample was eluted with 10 ml ethyl acetate/
heptane (1/1) and dried over anhydrous sodium sulfate. A silica Ba-
kerbond SPE was then pre-conditioned with 5 ml of ethyl acetate. The
sample from the C18 column was then loaded on this silica column,
rinsed with 5 ml ethyl acetate, eluted with 5 ml ethyl acetate/methanol
(1/1) and then dried under a nitrogen stream. 8-iso-PGF2K was deriv-
atized to penta£uorobenzyl (PFB) esters by the addition of 40 Wl 10%
PFB bromide in acetonitrile and 20Wl 10% N,N-diisopropylethylamine
in acetonitrile followed by a 20 min incubation at 37‡C. The mixture
was then dried under a nitrogen stream and this derivatization pro-
cedure was repeated. The residue was treated with 200 Wl of water and
extracted twice with 1 ml of diethyl ether. The organic phases were
decanted, combined and the solvent was evaporated. The sample was
resuspended in 50 Wl of methanol/chloroform (3/2) and subjected to a
TLC using Whatman LK6D silica gel TLC plates with the solvent
chloroform/ethanol (97/3). For the standard, 3^5 Wg PGF2K derivat-
ized as PFB esters was spotted on a separate TLC plate and visualized
by spraying with a 10% solution of phosphomolybdic acid in ethanol
followed by heating. By comparison with the migration distance of
the standard, compounds on the TLC plate containing the samples
migrating in the region of PGF2K (Rf about 0.23) and 1 cm on either
side were scraped o¡ and extracted twice with 1 ml ethyl acetate,
centrifuged and dried under a nitrogen stream. The formation of
trimethylsilyl (TMS) ether derivatives was performed by the addition
of 20 Wl N,O-bis(TMS)tri£uoroacetamide and 10 Wl dimethyl forma-
mide, incubated at room temperature overnight. Then, the samples
were dried under a nitrogen stream and ¢nally reconstituted in 50 Wl
undecane.
The GC separations were performed using a HP-5890 gas chroma-
tograph equipped with a HP-7673 autosampler (HP, Geneva, Switzer-
land). The column was a JpW Sci DB-1701 capillary column
30 mU0.32 mm I.D. with a 0.25 Wm ¢lm thickness (MSP-Friedli,
Koeniz, Switzerland). The oven heating was performed as follows:
90‡C (1 min), 30‡C/min up to 220‡C, 2‡C/min up to 280‡C, then,
15‡C up to 300‡C. Helium was used as carrier gas at a pressure of
10 psi. Samples (2^5 Wl) were injected in a cold on-column injector.
The MS and MS/MS experiments were carried out using a Finnigan
TSQ-700 mass spectrometer (Finnigan MAT, Bremen, Germany)
working in negative ionization mode at 200 eV using ammonia as
reagent gas and a source temperature set at 180‡C. GC/MS analyses
were done after selective monitoring of the [M-181]3 of the derivatives
of each compound. For the tandem mass spectrometric experiments
(GC/MS/MS), argon was used as collision gas, set to between 1 and
1.5 mTorr. A collision energy of 30 eV in the laboratory frame was
used. The transition [M-181]3C[M-181-3U90]3 was recorded for
each compound of interest.
Creatinine was measured by the modi¢ed Ja¡e¤ reaction procedure
using commercial kits (Sigma Diagnostics, Deisenhofen, Germany).
2.4. Statistical analysis
This is a pilot study with a low number of subjects involved (n = 4).
The data were analyzed by ANOVA with repeated measures using
Systat v 7.0 (SPSS, Zu«rich, Switzerland).
3. Results and discussion
3.1. E¡ect of urine sampling
Urine collection is simpler than plasma sampling because it
is a non-invasive procedure, sample handling and storage are
easier, and there is no evidence of artefactual formation of
isoprostanes during handling and storage, unlike plasma [5].
However, a 24 h urine collection required good compliance of
the volunteers and cannot be performed in most clinical sit-
uations while a single sample of urine is usually easy to ob-
tain. Isoprostane and MDA concentrations were determined
in urine samples, either those which were collected in the
morning or in the 24 h reconstituted samples. A good corre-
lation between the two sets of urine samples was obtained for
Fig. 1. MDA (A) and isoprostane (B) excretion in urine samples collected over 1 day. Urine was collected over 24 h in ¢ve di¡erent containers
according to time: fraction 1: 7^10 h, fraction 2: 10^14 h, fraction 3: 14^18 h, fraction 4: 18^22 h, fraction 5: 22^7 h. Results are expressed
as mean þ S.E.M.
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isoprostanes (y = 0.82U+0.67, r2 = 0.89, n = 20) and MDA
(y = 1.59U+0.62, r2 = 0.85, n = 27). In this study, we provide
strong evidence that isoprostanes determined in the urine col-
lected in the morning of the day adequately represent the daily
isoprostane excretion.
3.2. E¡ect of low lipid dietary intake
The assessment of in vivo lipid peroxidation is very prob-
lematic because the question arises whether the chosen bio-
marker re£ects only the in vivo lipid peroxidation of the sub-
ject or whether it re£ects also the absorption of oxidized lipid
products produced in the gut and/or present in the diet [7,8].
We, therefore, evaluated the isoprostane concentration in dif-
ferent dietary conditions.
The urinary isoprostane excretion was determined in the
¢ve urine samples collected at di¡erent time intervals over
1 day (Fig. 1). When entering the study, subjects exhibited
an isoprostane excretion of 3.428 þ 0.829 pmol/mg creatinine,
which is in agreement with that previously described for
healthy subjects [22]. The level of isoprostane excretion was
similar in all these ¢ve consecutive urine samples collected
over 24 h. In contrast, the level of MDA in the 14^18 h
sample (corresponding to the post-lunch period) tended to
be higher in comparison to the other four urine samples.
The MDA data are in agreement with data previously de-
scribed in the literature [7,8], showing that dietary MDA is
absorbed. These results demonstrate that daily isoprostane
excretion is not a¡ected by the dietary intake in contrast to
MDA.
To evaluate the e¡ect of dietary lipid intake on the excre-
tion of isoprostanes, volunteers were switched from their reg-
ular diet containing 35% fat as energy to an isocaloric-con-
trolled diet containing 5% fat as energy for 2 consecutive
days. At the beginning of the study, the urinary isoprostane
level was around 3.736 þ 0.314 pmol/mg creatinine (Fig. 2).
Interestingly, the inter-subject variability of the isoprostane
excretion was rather low, indicating that this group of four
subjects was rather homogenous. When the subjects consumed
the standardized low fat diet, their isoprostane excretion was
not signi¢cantly modi¢ed. When subjects returned to their
usual diet, the isoprostane level in urine remained stable.
These results demonstrate that isoprostane excretion is not
a¡ected by a marked reduction of the dietary lipid intake.
3.3. E¡ect of 1 day fasting
Fasting over 1 day is associated with lipolysis in adipose
tissue. After 1 day fasting, isoprostane excretion increased
signi¢cantly to 4.409 þ 0.547 pmol/mg creatinine (P6 0.005)
in all studied subjects (Fig. 3). On day 3, when the subjects
consumed their regular diet, isoprostane excretion returned to
the level observed on day 0. The urinary MDA excretion
pro¢le over the studied period mirrored that of isoprostanes.
Indeed, MDA started at 0.9 mmol/mg creatinine on day 0,
decreased by 50% on day 2 and returned back to initial values
on day 3. The increase of isoprostanes during fasting could be
due to the induction of an oxidative stress and/or due to the
release of isoprostanes from adipose tissue.
4. Conclusions
Evidence is growing that isoprostanes may represent a reli-
able and sensitive marker of in vivo lipid peroxidation that
can be assessed in plasma, urine and tissues. For the ¢rst time,
we demonstrate one of the criteria needed to establish isopros-
tanes as a reliable biomarker for assessing in vivo lipid per-
oxidation because they are not a¡ected by the lipid content of
the diet. Therefore, isoprostanes may be used in the future to
characterize the status of lipid peroxidation in di¡erent in vivo
situations such as in premature infants, in exercising subjects,
in ageing, in skin but also to evaluate the e⁄cacy of anti-
Fig. 2. Lack of an e¡ect of low dietary lipid intake on urinary iso-
prostane excretion. The volunteers ate their regular diet (35% of to-
tal energy as lipids) on day 1, a standardized low fat diet (5% of to-
tal energy as lipids) on day 2 and day 3 and then returned to their
regular diet on day 4. Results are expressed as mean þ S.E.M.
Fig. 3. E¡ect of 24 h fasting on urinary MDA (A) and isoprostane (B) excretion. The volunteers ate their regular diet on day 1, went through
a 24 h fasting on day 2 and returned to their regular diet on day 3. Results are expressed as mean þ S.E.M.
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oxidant molecules or cocktails to prevent or to reduce in vivo
lipid peroxidation.
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